This website uses cookies. For more information please contact us or consult our privacy policy.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- Comparative Effectiveness Research Provisions of the American Recovery and Reinvestment Act of 2009
Comparative Effectiveness Research Provisions of the American Recovery and Reinvestment Act of 2009
March 6, 2009, Covington E-Alert
April 29, 2010, Covington E-Alert
12/11/2008
WASHINGTON, DC, December 11, 2008 — Salix Pharmaceuticals, Ltd. announced that it has acquired rights to crofelemer from Napo Pharmaceuticals, Inc. Covington & Burling LLP represented Salix in the deal. Crofelemer currently is being investigated in a Phase 3 study as an anti-diarrheal agent for the treatment of chronic diarrhea in people living with HIV. Salix ...
May 3, 2007, Covington E-Alert